Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10864MR)

This product GTTS-WQ10864MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Melanoma, Neuroblastoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001276468.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10864MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4510MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ4452MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ14447MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ5169MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ9529MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ10003MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ5909MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CIM 331
GTTS-WQ3141MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA APT070
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW